Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude du RC48-ADC pour le traitement du cancer du sein localement avancé ou métastatique avec une faible expression de HER2

20 septembre 2026 mis à jour par: RemeGen Co., Ltd.

Étude clinique randomisée, contrôlée et multicentrique de phase III évaluant l'efficacité et l'innocuité du RC48-ADC pour le traitement du cancer du sein localement avancé ou métastatique avec une faible expression de HER2

This study will compare RC48-ADC to physician choice standard treatment. Participants must have HER2-low breast cancer ,previous use of anthracyclines, and have been treated with one or two systemic chemotherapy regimens following recurrence/metastasis.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

This study is a multi-center, randomized, open, parallel control to evaluate the effectiveness and safety of Phase III clinical trials of the efficacy and safety of recombinant humanized anti-HER2 monoclonal antibody-Monomethyl auristatin E (MMAE) conjugate for the treatment of locally advanced or metastatic breast cancer the study.The low expression of HER2 is defined as: the immunohistochemistry (IHC) confirmed by the central laboratory detects the expression of HER2 protein as IHC 2+ and the fluorescence in situ hybridization (FISH) detection has no amplification.

Type d'étude

Interventionnel

Inscription (Estimé)

366

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Binghe Xu, M.D.
  • Numéro de téléphone: 010-87788826
  • E-mail: bhxu@hotmail.com

Lieux d'étude

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100021
        • Recrutement
        • Oncology Hospital, Chinese Academy of Medical Sciences
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 70 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Voluntarily agree to participate in the study and sign the informed consent;
  • Subjects aged 18-70 years (including 18 years and 70 years) and not reaching the 71st birthday were all considered to be ≤70 years old;
  • Expected survival ≥12 weeks;
  • Eastern Cooperative Oncology Group(ECOG) physical condition 0 or 1;
  • For female subjects of child-bearing age women agreed to study during treatment and experimental subjects within 6 months after the end of the treatment period using an approved by the medical contraception (e.g. intrauterine device, the pill or condoms), before the study drug delivery within 7 days of pregnancy blood test must be negative (sterilization surgery or age 60 or more subjects can choose no pregnancy blood test), and must be an lactation. For male subjects: should be sterilized surgically, or agree to use a medically approved contraceptive method during the study period and for 6 months after the end of the treatment period. Control subjects after the end of the treatment period according to the choice of control drugs to determine the length of contraception.
  • Able to understand the study requirements and be willing and able to follow the study and follow-up procedures.
  • Bone marrow function:

hemoglobin ≥9g/dL; absolute neutrophil count ≥1.5×109/L; white blood cell count ≥3.0×109/L platelet ≥100 ×109/L;

  • Liver function (according to the normal value of the clinical trial center) :

serum total bilirubin ≤1.5 times the upper limit of normal value (ULN); alanine aminotransferase (ALT), aspartate aminotransferase(AST) and Alkaline phosphatase(ALP) were ≤2.5 × ULN in the absence of liver metastasis, and ALT, AST and Alkaline phosphatase(ALP) were ≤5 × ULN in the presence of liver metastasis

  • Renal function (according to the normal value of the clinical trial center) :

serum creatinine ≤1.5×ULN, or calculated by Cockcroft-Gault formula, the creatinine clearance rate (CrCl) ≥60 mL/min;

  • Cardiac function:

American New York college of cardiology (NYHA) grade < 3; left ventricular ejection fraction ≥50%;

  • Breast cancer subjects diagnosed by histology and / or cytology are currently at a locally advanced or metastatic stage and cannot be radically removed;
  • The low expression of HER2 confirmed by the IHC and FISH results of the central laboratory (defined as: IHC 2+ and no amplification of FISH); the subject can provide a specimen of the primary or metastatic tumor site (paraffin wax) for HER2 detection Block, paraffin-embedded section or fresh tissue section can be used);
  • Previous use of anthracycline drugs;
  • Received 1 or 2 systemic chemotherapy treatments after relapse / metastasis. Subjects who relapsed during adjuvant chemotherapy or within 12 months after the end of adjuvant chemotherapy were considered to have failed first-line chemotherapy after relapse / metastasis.
  • Hormone receptors are negative or positive. Hormone receptor-positive subjects need to progress after receiving endocrine therapy after relapse / metastasis or relapse after less than 2 years. Patients who are not suitable for endocrine therapy can be included in this study after undergoing chemotherapy treatment (first-line or second-line);
  • The imaging evidence confirmed by the investigator that the tumor disease progressed during or after the most recent treatment is required;
  • There has been no diagnosis of HER2 positive (HER2 IHC 3+ or FISH amplification)
  • Have not used drugs targeting HER2 (including antibodies, small molecule Tyrosine kinase inhibitor(TKIs) and antibody drug conjugates).
  • According to the RECIST 1.1 standard, there is at least one measurable lesion.

Exclusion Criteria:

  • Received chemotherapy within 4 weeks before the start of study administration (treatment with nitrosourea and mitomycin C within 6 weeks, oral fluorouracil within 2 weeks), radiotherapy (palliative for bone metastases Local radiotherapy is within 2 weeks before study administration), immunotherapy; received endocrine therapy for breast cancer within 2 weeks before study administration;
  • The research drug was used within 4 weeks before the start of study administration;
  • Have undergone major surgery within 4 weeks before the start of study administration;
  • Have received a live vaccine within 4 weeks before the start of study administration or plan to receive any vaccine during the study period;
  • Serious cardiovascular and cerebrovascular events occurred within 12 months, including but not limited to unstable angina, myocardial infarction, cerebral hemorrhage, and cerebral infarction (except for asymptomatic and untreated lacunar infarction);
  • Those who are suffering from heart disease are not suitable for enrollment, including but not limited to arrhythmia and heart failure requiring medical treatment or accompanied by symptoms;
  • There are other lung diseases requiring treatment or serious, including but not limited to active pulmonary tuberculosis, interstitial lung disease, etc ;
  • Suffering from active infection requiring systemic treatment;
  • Have active autoimmune diseases (such as the use of corticosteroids or immunosuppressive drugs, etc.) that require systemic treatment within the past 2 years, allowing related alternative treatments (such as thyroxine, insulin, or the physiology of adrenal or pituitary insufficiency Corticosteroid replacement therapy);
  • The toxicity of the previous anti-tumor therapy has not been restored to the 0 to 1 level defined by CTCAE version 5.0, of which the neurotoxicity has not been restored to 0; except for hair loss, pigmentation or other researches that do not increase the risk of medication Happening;
  • Have a clear past or current history of neurological or mental disorders, including epilepsy or dementia;
  • According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the clinical study;
  • Positive HIV test results; patients with active hepatitis B or C (HBsAg positive and hepatitis B virus(HBV) DNA titers above the upper limit of normal; Hepatitis C Virus Antibody(HCVAb) positive hepatitis C virus (HCV) RNA titers above the upper limit of normal);
  • There is a third interstitial fluid that cannot be controlled by drainage or other methods (including a large amount of pleural effusion or ascites);
  • Known hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or similar drugs;
  • Subjects who are not suitable for using any of the alternative control drugs;
  • The presence of brain metastases and / or cancerous meningitis;
  • Have other malignant tumors within 5 years before signing the informed consent form (except for non-melanoma skin cancer, cervical carcinoma in situ or other tumors that have been effectively treated, except malignant tumors that are considered cured);
  • Subjects who are estimated to be inadequate for patients to participate in this clinical study or other factors that the investigator believes are inappropriate to participate in this study;

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: RC48-ADC

RC48-ADC common name:Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection Dosage form:Lyophilized powder injection specification:60 mg / piece Medication plan:Every 2 weeks Expiration date:18 months HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.

RC48-ADC 2.0mg / kg, intravenous drip, once every 2 weeks

Autres noms:
  • RC48
Comparateur actif: Physician's Choice

Physician's Choice:

HER2-low, unresectable, locally advanced or metastatic breast cancer participants previously treated with anthracycline and received 1 or 2 systemic chemotherapy after relapse / metastasis.

Physician's choice from the following options:

Paclitaxel Injection Docetaxel Injection Vinorelbine Tartrate Injection Capecitabine Tablets

Administered according to label, as one option for Physician's Choice (determined before randomization)

Autres noms:
  • Taxol

Administered according to label, as one option for Physician's Choice (determined before randomization)

Autres noms:
  • Taxotère

Administered according to label, as one option for Physician's Choice (determined before randomization)

Autres noms:
  • Navelbine

Administered according to label, as one option for Physician's Choice (determined before randomization)

Autres noms:
  • Xeloda

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee
Délai: within approximately 3 years

Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

within approximately 3 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS), evaluated by the investigator
Délai: within approximately 3 years

Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard.

within approximately 3 years
Objective remission rate (ORR)
Délai: within approximately 3 years

The objective response rate will be mainly analyzed by the independent efficacy evaluation committee according to the RECIST 1.1 standard tumor evaluation (the evaluation by the investigator will also be performed).

within approximately 3 years
Duration of relief (DOR)
Délai: within approximately 3 years

DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

within approximately 3 years
Disease control rate (DCR)
Délai: within approximately 3 years

Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.

within approximately 3 years
Tumor progression time (TTP)
Délai: within approximately 3 years

Time to disease progression (TTP) refers to the time from the random date to the first disease progression (calculated by the event that occurred first). Disease progression will be evaluated by the investigator according to the RECIST 1.1 standard (investigator and Independent Review Committee(IRC) evaluation).

within approximately 3 years
Overall survival (OS)
Délai: within approximately 3 years

Overall survival (OS) refers to the time from the date of randomization to the date of death of the subject.

within approximately 3 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Yu Jiang, West China Hospital
  • Chercheur principal: Binghe Xu, Oncology Hospital, Chinese Academy of Medical Sciences
  • Chercheur principal: Wei Li, Jilin University First Hospital
  • Chercheur principal: Xiaojia Wang, Zhejiang Cancer Hospital
  • Chercheur principal: Ying Wang, Sun Yat-sen University Cancer Prevention and Control Center
  • Chercheur principal: Ning Liao, Guangdong Provincial People's Hospital
  • Chercheur principal: Haibo Wang, Qingdao University Hospital
  • Chercheur principal: Quchang Ouyang, Hunan Cancer Hospital
  • Chercheur principal: Yueyin Pan, Anhui Provincial Hospital
  • Chercheur principal: Yingying Du, The First Affiliated Hospital of Anhui Medical University
  • Chercheur principal: Jin Yang, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine
  • Chercheur principal: Xiuwen Wang, Qilu Hospital of Shandong University
  • Chercheur principal: Huihua Xiong, Tongji Hospital
  • Chercheur principal: Xinhong Wu, Hubei Cancer Hospital
  • Chercheur principal: Weimin Xie, Cancer Hospital Affiliated to Guangxi Medical University
  • Chercheur principal: Xin Zhou, Chongqing University Cancer Hospital
  • Chercheur principal: Li Ran, Cancer Hospital of Guizhou Province
  • Chercheur principal: Yu Wang, Shanxi Province Cancer Hospital
  • Chercheur principal: Jinnan Gao, Bethune Hospital of Shanxi Province
  • Chercheur principal: Jingfen Wang, Linyi Cancer Hospital
  • Chercheur principal: Xianhe Xie, First Affiliated Hospital of Fujian Medical University
  • Chercheur principal: Ru Zeng, The First Affiliated Hospital of Xiamen University
  • Chercheur principal: Airong Wang, Weihai Municipal Hospital
  • Chercheur principal: Zhengqiu Zhu, The Affiliated Hospital of Xuzhou Medical University
  • Chercheur principal: Sanyuan Sun, Xuzhou Central Hospital
  • Chercheur principal: Qingshan Li, Affiliated Hospital of Chengde Medical College
  • Chercheur principal: Aimin Zang, Affiliated Hospital of Hebei University
  • Chercheur principal: Liuzhong Yang, The First Affiliated Hospital of Xinxiang Medical College
  • Chercheur principal: Meili Sun, Jinan Central Hospital
  • Chercheur principal: Liang Li, Zibo Central Hospital
  • Chercheur principal: Guohua Yu, Weifang People's Hospital
  • Chercheur principal: Xujuan Wang, Neijiang Second People's Hospital
  • Chercheur principal: Ying Wang, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Chercheur principal: Ying Cheng, Jilin Provincial Tumor Hospital
  • Chercheur principal: Jifeng Feng, Jiangsu Cancer Institute & Hospital
  • Chercheur principal: Tao Sun, Liaoning Cancer Hospital & Institute
  • Chercheur principal: Yuee Teng, First Hospital of China Medical University
  • Chercheur principal: Shu Wang, Peking University People's Hospital
  • Chercheur principal: Min Yan, Henan Cancer Hospital
  • Chercheur principal: Changlu Hu, Anhui Provincial Cancer Hospital
  • Chercheur principal: Zhongsheng Tong, Tianjin Cancer Hospital Airport Hospital
  • Chercheur principal: Lihua Song, Shandong Cancer Hospital and Institute
  • Chercheur principal: Yunjiang Liu, Hebei Medical University Fourth Hospital
  • Chercheur principal: Jing Cheng, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • Chercheur principal: Peng Shen, First Affiliated Hospital of Zhejiang University
  • Chercheur principal: Liangming Zhang, Yantai Yuhuangding Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

29 septembre 2020

Achèvement primaire (Estimé)

31 décembre 2027

Achèvement de l'étude (Estimé)

31 décembre 2027

Dates d'inscription aux études

Première soumission

30 avril 2020

Première soumission répondant aux critères de contrôle qualité

19 mai 2020

Première publication (Réel)

22 mai 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • RC48-C012

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .